HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial

التفاصيل البيبلوغرافية
العنوان:	HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial
المؤلفون:	Ahmed, Khatija, Baeten, Jared M, Beksinska, Mags, Bekker, Linda-Gail, Bukusi, Elizabeth A, Donnell, Deborah, Gichangi, Peter B, Heller, Kate B, Hofmeyr, G Justus, Justman, Jessica, Kasaro, Margaret Phiri, Kiarie, James, Louw, Cheryl, Mastro, Timothy D, Morrison, Charles S, Mugo, Nelly R, Nair, Gonasagrie, Nanda, Kavita, Nhlabatsi, Zelda, Onono, Maricianah, Palanee-Phillips, Thesla, Pleaner, Melanie, Rees, Helen, Singata-Madliki, Mandisa, Scoville, Caitlin W, Selepe, Raesibe Agnes Pearl, Shears, Kathleen, Sibiya, Sydney, Smit, Jennifer, Steyn, Petrus S, Stringer, Jeffrey, Taylor, Douglas, Thomas, Katherine K, Welch, Julia D
المصدر:	The Lancet; July-August 2019, Vol. 394 Issue: 10195 p303-313, 11p
مستخلص:	Observational and laboratory studies suggest that some hormonal contraceptive methods, particularly intramuscular depot medroxyprogesterone acetate (DMPA-IM), might increase women's susceptibility to HIV acquisition. We aimed to compare DMPA-IM, a copper intrauterine device (IUD), and a levonorgestrel (LNG) implant among African women seeking effective contraception and living in areas of high HIV incidence.
قاعدة البيانات:	Supplemental Index

الوصف
تدمد:	01406736 1474547X
DOI:	10.1016/S0140-6736(19)31288-7